FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2050366955> ?p ?o ?g. }

• W2050366955 endingPage "651" @default.
• W2050366955 startingPage "648" @default.
• W2050366955 abstract "Study Type – Prognosis (case series) Level of Evidence 4 OBJECTIVE To determine if the testosterone level achieved with androgen‐deprivation therapy (ADT) is directly related to survival and risk of death in men with metastatic prostate cancer, as agonistic analogues of luteinizing hormone‐releasing hormones (LHRH) are indicated for palliative treatment of these patients, but there is no consensus about the utility of serum testosterone measurements during the follow‐up, and their possible prognostic value. PATIENTS AND METHODS We retrospectively reviewed 129 consecutive patients with a histological diagnosis of metastatic bony‐only prostate cancer and previously untreated with ADT. They were treated with 3 months of goserelin. Testosterone and prostate‐specific antigen (PSA) levels were measured in all patients every 3 months for the duration of the follow‐up. The following variables were recorded: age, stage, Gleason score, basal PSA level, basal testosterone level, PSA nadir, time to PSA nadir, testosterone after 6 months, testosterone nadir and time to testosterone nadir. Data were analysed using Cox’s proportional hazards models, with the primary endpoint being cancer‐specific survival. RESULTS The mean ( sd ) basal PSA level was 185.8 (344.1) ng/mL, and the mean nadir PSA level 2.7 (8.6) ng/mL. The mean testosterone levels at baseline, 6 months and the nadir were 440 (200), 40 (40) and 21 (15) ng/dL. With a mean follow‐up of 47.5 (29.7) months, 71 patients were dead (55%) and 78 were alive (45%) at the time of analysis. Statistical analysis using Cox’s model showed that in these patients the risk of death was directly correlated not only to Gleason score ( P < 0.01) and to the 6‐month PSA level ( P < 0.01), but also to the 6‐month serum testosterone level (hazard ratio 1.32, P < 0.05). CONCLUSION These results suggest a direct correlation between the risk of death and testosterone levels achieved during ADT. Based on the present results, lowering the testosterone level as much as possible should be the goal of ADT in patients with metastatic prostate cancer, as this might affect patient survival." @default.
• W2050366955 created "2016-06-24" @default.
• W2050366955 creator A5025885478 @default.
• W2050366955 creator A5030545731 @default.
• W2050366955 creator A5053361003 @default.
• W2050366955 date "2010-02-11" @default.
• W2050366955 modified "2023-10-18" @default.
• W2050366955 title "Testosterone levels in patients with metastatic prostate cancer treated with luteinizing hormone-releasing hormone therapy: prognostic significance?" @default.
• W2050366955 cites W155079562 @default.
• W2050366955 cites W1604487436 @default.
• W2050366955 cites W1983276304 @default.
• W2050366955 cites W1996291876 @default.
• W2050366955 cites W2002307498 @default.
• W2050366955 cites W2034168075 @default.
• W2050366955 cites W2038415989 @default.
• W2050366955 cites W2053626765 @default.
• W2050366955 cites W2055051372 @default.
• W2050366955 cites W2056553137 @default.
• W2050366955 cites W2074555962 @default.
• W2050366955 cites W207533397 @default.
• W2050366955 cites W2088482465 @default.
• W2050366955 cites W2112304044 @default.
• W2050366955 cites W2113092779 @default.
• W2050366955 cites W2159437944 @default.
• W2050366955 cites W2163566079 @default.
• W2050366955 cites W2165564512 @default.
• W2050366955 cites W4293314646 @default.
• W2050366955 cites W437930 @default.
• W2050366955 doi "https://doi.org/10.1111/j.1464-410x.2009.08814.x" @default.
• W2050366955 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19747358" @default.
• W2050366955 hasPublicationYear "2010" @default.
• W2050366955 type Work @default.
• W2050366955 sameAs 2050366955 @default.
• W2050366955 citedByCount "139" @default.
• W2050366955 countsByYear W20503669552012 @default.
• W2050366955 countsByYear W20503669552013 @default.
• W2050366955 countsByYear W20503669552014 @default.
• W2050366955 countsByYear W20503669552015 @default.
• W2050366955 countsByYear W20503669552016 @default.
• W2050366955 countsByYear W20503669552017 @default.
• W2050366955 countsByYear W20503669552018 @default.
• W2050366955 countsByYear W20503669552019 @default.
• W2050366955 countsByYear W20503669552020 @default.
• W2050366955 countsByYear W20503669552021 @default.
• W2050366955 countsByYear W20503669552022 @default.
• W2050366955 countsByYear W20503669552023 @default.
• W2050366955 crossrefType "journal-article" @default.
• W2050366955 hasAuthorship W2050366955A5025885478 @default.
• W2050366955 hasAuthorship W2050366955A5030545731 @default.
• W2050366955 hasAuthorship W2050366955A5053361003 @default.
• W2050366955 hasConcept C121608353 @default.
• W2050366955 hasConcept C126322002 @default.
• W2050366955 hasConcept C126894567 @default.
• W2050366955 hasConcept C127413603 @default.
• W2050366955 hasConcept C143998085 @default.
• W2050366955 hasConcept C146978453 @default.
• W2050366955 hasConcept C19269812 @default.
• W2050366955 hasConcept C2777911890 @default.
• W2050366955 hasConcept C2778024521 @default.
• W2050366955 hasConcept C2778575703 @default.
• W2050366955 hasConcept C2779279991 @default.
• W2050366955 hasConcept C2779306644 @default.
• W2050366955 hasConcept C2780192828 @default.
• W2050366955 hasConcept C2781406297 @default.
• W2050366955 hasConcept C50382708 @default.
• W2050366955 hasConcept C71315377 @default.
• W2050366955 hasConcept C71924100 @default.
• W2050366955 hasConcept C88575799 @default.
• W2050366955 hasConceptScore W2050366955C121608353 @default.
• W2050366955 hasConceptScore W2050366955C126322002 @default.
• W2050366955 hasConceptScore W2050366955C126894567 @default.
• W2050366955 hasConceptScore W2050366955C127413603 @default.
• W2050366955 hasConceptScore W2050366955C143998085 @default.
• W2050366955 hasConceptScore W2050366955C146978453 @default.
• W2050366955 hasConceptScore W2050366955C19269812 @default.
• W2050366955 hasConceptScore W2050366955C2777911890 @default.
• W2050366955 hasConceptScore W2050366955C2778024521 @default.
• W2050366955 hasConceptScore W2050366955C2778575703 @default.
• W2050366955 hasConceptScore W2050366955C2779279991 @default.
• W2050366955 hasConceptScore W2050366955C2779306644 @default.
• W2050366955 hasConceptScore W2050366955C2780192828 @default.
• W2050366955 hasConceptScore W2050366955C2781406297 @default.
• W2050366955 hasConceptScore W2050366955C50382708 @default.
• W2050366955 hasConceptScore W2050366955C71315377 @default.
• W2050366955 hasConceptScore W2050366955C71924100 @default.
• W2050366955 hasConceptScore W2050366955C88575799 @default.
• W2050366955 hasIssue "5" @default.
• W2050366955 hasLocation W20503669551 @default.
• W2050366955 hasLocation W20503669552 @default.
• W2050366955 hasOpenAccess W2050366955 @default.
• W2050366955 hasPrimaryLocation W20503669551 @default.
• W2050366955 hasRelatedWork W1936443018 @default.
• W2050366955 hasRelatedWork W1974203140 @default.
• W2050366955 hasRelatedWork W2043483232 @default.
• W2050366955 hasRelatedWork W2053295005 @default.
• W2050366955 hasRelatedWork W2077214840 @default.
• W2050366955 hasRelatedWork W2122018218 @default.
• W2050366955 hasRelatedWork W2495312616 @default.

• next